MAP2K7 and Hyperkeratosis: Overall, 0.20% of patients from the BRAF and MEK inhibitor treatment group had a decrease in hyperkeratosis compared with 1.35% in the control group, and 0.00% of patients in the BRAF and MEK treatment group developed palmoplantar erythrodysaesthesia syndrome, compared with 3.99% in the BRAF inhibitor control group.